Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 03, 2026
AMC Networks (AMCX) +6% Gains on Netflix Deal for The Walking Dead Universe

AMC Networks (AMCX) +6% Gains on Netflix Deal for The Walking Dead Universe

Key Takeaways

  • AMC Networks shares have gained approximately 6% over the last 30 days, moving from around $10.26 in early July to roughly $10.90 in early August, driven largely by a landmark licensing agreement with Netflix.
  • The company announced a five-year, $500 million co-exclusive global streaming deal with NFLX for the entire The Walking Dead universe, covering seven series and 371 episodes.
  • Q2 2026 results reflected ongoing revenue pressure — consolidated revenue fell 9% year-over-year to $547.5 million — but management called the quarter the expected trough for adjusted operating income.
  • Full-year 2026 guidance was raised materially: consolidated revenue of $2.40–$2.45 billion, adjusted operating income of $410–$420 million, and free cash flow of roughly $220 million.
  • Wall Street remains cautious, with a consensus "Reduce" rating and an average 12-month price target of $8.50, though several analysts raised targets following the Netflix announcement.
  • The stock hit a 52-week high of $11.66 on July 31 following the Q2 report and licensing news before settling near $10.90 in subsequent sessions.

Current Market Snapshot

AMC Networks, now operating under the brand name AMC Global Media, has seen its stock trade in a volatile range between roughly $9.30 and $11.66 over the past several weeks. After spending much of June and early July in the $9.30–$10.30 zone, shares surged more than 15% on July 31 when the company released second-quarter results alongside the Netflix licensing pact. The stock moved above its 200-day moving average of approximately $8.52 in mid-July and has stayed there since, reflecting a shift in sentiment. Even so, AMCX continues to trade at a modest price-to-sales multiple of approximately 0.25, which tells me the market is still skeptical about the durability of the legacy linear television business even as streaming and licensing show renewed momentum. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

AMC Networks (AMCX) Business Overview and Competitive Position

AMC Networks is a global entertainment company that develops, produces, and distributes premium content across television and streaming platforms. Its portfolio includes linear cable networks — AMC, WE tv, BBC America, IFC, and SundanceTV — as well as a growing suite of targeted direct-to-consumer streaming services: AMC+, Acorn TV, Shudder, Sundance Now, ALLBLK, HIDIVE, and All Reality. The company also operates AMC Studios, the in-house production arm behind major franchises including The Walking Dead and the Anne Rice Immortal Universe. Following international divestitures completed in 2023, domestic operations now account for nearly 90% of total revenue. The company differentiates itself by owning a deep library of original intellectual property and by catering to passionate niche audiences rather than competing head-to-head with large-scale general-entertainment streaming platforms. Investors track AMCX closely as a bellwether for how mid-tier media companies can monetize legacy content libraries in an increasingly streaming-first landscape.

Recent Developments Driving AMCX

The single most consequential event in the last 30 days was the July 30 disclosure of a five-year, $500 million global co-exclusive streaming licensing agreement with NFLX covering the entire The Walking Dead franchise — all seven series and 371 episodes. Under the terms, AMC Networks expects to recognize roughly $445 million in total revenue over the deal's life, with $200 million to $225 million recognized in both 2026 and 2027. The original Walking Dead series is also set to return to AMC+ in January 2027 for the first time.

The licensing news overshadowed otherwise weak second-quarter financial results. Consolidated revenue declined 9% year-over-year to $547.5 million, missing analyst estimates, while the company reported an adjusted loss of $0.28 per share. Domestic subscription revenue dropped 5% as a 17% decline in affiliate fees more than offset 6% streaming revenue growth. Advertising revenue was also pressured, though digital advertising grew 44% compared to the prior-year period.

On the analyst front, Morgan Stanley raised its price target to $10 from $7 while maintaining an Underweight rating, citing the deal's validation of AMC's intellectual property alongside ongoing concerns about subscriber growth and secular industry headwinds. Wells Fargo lifted its target to $11 from $10 with an Equal Weight rating. The broader analyst consensus remains cautious, with two Sell and two Hold ratings and an average price target of $8.50.

On the balance sheet, AMC repaid its remaining Term Loan A and terminated its credit facility during the quarter. The company ended Q2 with approximately $464 million in cash against roughly $1.3 billion in net debt, with approximately 75% of total debt not maturing until July 2032. From what I see, this debt profile provides some breathing room as the company executes on its new licensing strategy.

2026 Outlook and What Investors Should Watch

The raised full-year 2026 guidance — $2.40 billion to $2.45 billion in revenue, $410 million to $420 million in adjusted operating income, and roughly $220 million in free cash flow — sets a higher bar for the second half of the year. Management expects both revenue and profitability to improve from Q2 levels as licensing revenue from the Netflix deal begins flowing and distribution agreements with major pay-TV providers such as CMCSA and GOOG-owned YouTube take effect.

Key factors to monitor include the pace of affiliate revenue decline in the domestic linear business, the trajectory of streaming subscriber acquisition following the company's decision to stop reporting subscriber figures quarterly, and the sustainability of digital advertising growth. The company's ability to execute on content licensing beyond The Walking Dead will also be critical — investors will look for evidence that AMC can replicate its IP monetization playbook across other franchises, including the Anne Rice universe. Macroeconomic considerations such as advertising market health, consumer discretionary spending trends, and competitive dynamics in streaming remain important external variables. With net leverage at 4.1 times and a concentrated franchise portfolio, AMC's margin for operational missteps remains limited heading into 2027.

Using Tickeron’s Trending AI Robots

In my own research, I occasionally review Tickeron’s Trending AI Robots page to see how top-performing bots are positioned across various tickers. It offers a curated look at algorithmic strategies that can help put data-driven context around names like AMCX without adding emotional bias to the process.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AMCX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


AMCX in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 01, 2026

AMCX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 41 cases where AMCX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +1.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMCX advanced for three days, in 209 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMCX as a result. In 69 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for AMCX turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 35 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

AMCX moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AMCX crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMCX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for AMCX entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. AMCX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.545) is normal, around the industry mean (18.508). P/E Ratio (11.523) is within average values for comparable stocks, (97.633). Projected Growth (PEG Ratio) (0.545) is also within normal values, averaging (3.885). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.271) is also within normal values, averaging (2.913).

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMCX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.

Notable companies

The most notable companies in this group are Netflix Inc. (NASDAQ:NFLX), Walt Disney Company (The) (NYSE:DIS), Roku (NASDAQ:ROKU), Paramount Skydance Corporation (NASDAQ:PSKY), AMC Entertainment Holdings (NYSE:AMC), iQIYI (NASDAQ:IQ), HUYA (NYSE:HUYA).

Industry description

Movies/entertainment industry include companies that produce and distribute motion pictures, and companies that operate general entertainment facilities like amusement parks and bowling centers. Some companies in this industry also have professional sports franchises. Live Nation Entertainment, Inc., Liberty Media Corp. and Viacom Inc. are some of the biggest companies in this space.

Market Cap

The average market capitalization across the Movies/Entertainment Industry is 17.55B. The market cap for tickers in the group ranges from 293 to 288.27B. NFLX holds the highest valuation in this group at 288.27B. The lowest valued company is BLMZF at 293.

High and low price notable news

The average weekly price growth across all stocks in the Movies/Entertainment Industry was -4%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 0%. STRZ experienced the highest price growth at 7%, while CPOP experienced the biggest fall at -33%.

Volume

The average weekly volume growth across all stocks in the Movies/Entertainment Industry was 79%. For the same stocks of the Industry, the average monthly volume growth was 163% and the average quarterly volume growth was 102%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 65
P/E Growth Rating: 47
Price Growth Rating: 58
SMR Rating: 83
Profit Risk Rating: 76
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
AMCX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an operator of cable television networks through its subsidiaries

Industry MoviesEntertainment

Industry
Cable Or Satellite TV
Address
11 Penn Plaza
Phone
N/A
Employees
1738
Web
https://www.amcglobalmedia.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
Sable Offshore Corp. (SOC) shares fell 7.40% in the most recent completed session, closing at $16.52 versus a prior close of $17.84. The pullback followed a volatile stretch in which SOC traded between $15.76 and $19.21 over just two sessions, reflecting profit‑taking after a strong run in March.
NBR stock rose approximately +12% over the last 30 days, driven by positive momentum in the oil and gas drilling sector and strong Q4 earnings beat. Over the past quarter, the stock surged +58%, fueled by robust YTD performance, debt reduction efforts, and improved operational results in international drilling.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).